Department of Pathology, Shenzhen Second People's Hospital, Shenzhen, Guangdong, China.
Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong.
Oncologist. 2017 Nov;22(11):1316-1324. doi: 10.1634/theoncologist.2017-0029. Epub 2017 Jul 12.
The presence of tumor infiltrating lymphocytes (TIL) is associated with favorable prognosis. Recent evidence suggested that not only their density, but also the spatial organization as tertiary lymphoid structures (TLS), play a key role in determining patient survival.
In a cohort of 248 breast cancers, the clinicopathologic association and prognostic role of TLS was examined.
Tertiary lymphoid structures were associated with higher tumor grade, apocrine phenotype, necrosis, extensive in situ component, lymphovascular invasion (LVI), and high TIL. For biomarkers, TLS were associated with hormone receptors negativity, HER2 positivity, and c-kit expression. Tertiary lymphoid structures were significantly related to better disease-free survival (DFS) in HER2 positive (HER2+) breast cancers (log-rank = 4.054), which was not dependent on high TIL status. The combined TLS and TIL status was an independent favorable factor associated with DFS in those cases. Interestingly, tumor cell infiltration into the TLS was found in 41.9% of TLS positive cases. It was associated with LVI in HER2 negative (HER2-) TLS positive (particularly estrogen receptor positive [ER+] HER2-) cases. In the ER+ HER2- cases, tumor cell infiltration into TLS was also associated with increased pathologic nodal stage (pN) stage and nodal involvement.
Tertiary lymphoid structures showed a similar relationship with clinicopathologic features and biomarkers as TIL. The presence of TLS, irrespective of TIL level, could be an important favorable prognostic indicator in HER2+ breast cancer patients. Given the significance of TLS in promoting effective antitumor immunity, further understanding of its organization and induction may provide new opportunities to improve the current immunotherapy strategies.
Despite recent interest on the clinical value of tumor infiltrating lymphocyte (TIL), little was known on the clinical significance on their spatial organization as tertiary lymphoid structures (TLS). Although TLS showed similar relationships with clinicopathologic features and biomarkers as TIL, the prognostic value of TLS, particularly in HER2 positive cancers, was independent of TIL. Moreover, tumor infiltration could be present in TLS which appears to be related to tumor invasion in HER2 negative cancers. Overall, the results demonstrated the additional value for TLS in HER2 cancer subtypes. Further investigations and its standardized evaluation will enhance its use as standard practice.
肿瘤浸润淋巴细胞(TIL)的存在与预后良好相关。最近的证据表明,TIL 的密度及其作为三级淋巴结构(TLS)的空间组织都在决定患者生存方面起着关键作用。
在 248 例乳腺癌患者的队列中,检查了 TLS 的临床病理关联和预后作用。
TLS 与肿瘤分级较高、大汗腺表型、坏死、广泛原位成分、淋巴血管侵犯(LVI)和高 TIL 相关。在生物标志物方面,TLS 与激素受体阴性、HER2 阳性和 c-kit 表达相关。TLS 与 HER2 阳性(HER2+)乳腺癌的无病生存(DFS)显著相关(log-rank=4.054),且不依赖于高 TIL 状态。TLS 与 TIL 状态相结合是与这些病例 DFS 相关的独立有利因素。有趣的是,在 41.9%的 TLS 阳性病例中发现了肿瘤细胞浸润到 TLS 中。它与 HER2 阴性(HER2-)TLS 阳性(尤其是雌激素受体阳性[ER+]HER2-)病例中的 LVI 相关。在 ER+HER2-病例中,肿瘤细胞浸润到 TLS 也与增加的病理淋巴结分期(pN)和淋巴结受累相关。
TLS 与 TIL 具有相似的临床病理特征和生物标志物关系。TLS 的存在,无论 TIL 水平如何,都可能是 HER2+乳腺癌患者的一个重要有利预后指标。鉴于 TLS 在促进有效的抗肿瘤免疫方面的重要意义,进一步了解其组织和诱导可能为改善当前免疫治疗策略提供新的机会。
尽管最近对肿瘤浸润淋巴细胞(TIL)的临床价值产生了兴趣,但对其作为三级淋巴结构(TLS)的空间组织的临床意义知之甚少。尽管 TLS 与 TIL 具有相似的临床病理特征和生物标志物关系,但 TLS 的预后价值,特别是在 HER2 阳性癌症中,与 TIL 无关。此外,肿瘤细胞浸润可能存在于 TLS 中,这似乎与 HER2 阴性癌症中的肿瘤浸润有关。总体而言,该结果表明 TLS 在 HER2 癌症亚型中的额外价值。进一步的研究和其标准化评估将增强其作为标准实践的使用。